文献速递神经肿瘤

NLGN4X TCR转基因T细胞治疗胶质瘤

NLGN4X TCR transgenic T cells to treat gliomas.
PubMed 文献 · Neuro Oncol · 2024-01-01

研究通过疫苗接种后单细胞TCR测序鉴定出HLA-A*02限制性NLGN4X特异性TCR,构建NLGN4X-TCR-T细胞,在体外证实其反应性、细胞毒性和多功能性,并在NLGN4X表达实验性胶质瘤NSG MHC I/II KO小鼠中经脑室内给药延长生存,客观缓解率为44.4%,对照组为0.0%。

要点

  • 疫苗诱导的HLA-A*02限制性NLGN4X131-139特异性TCR可用于临床前治疗。
  • NLGN4X-TCR-T在多种细胞模型中显示反应性、细胞毒性和多功能性。
  • 脑室内给予NLGN4X-TCR-T使实验性胶质瘤小鼠生存延长,客观缓解率44.4% vs 对照组0.0%。

核心结论

  • NLGN4X-TCR-T在临床前胶质母细胞瘤模型中显示疗效。
  • 研究首次提供证据表明可治疗性获取疫苗诱导的人源TCR用于胶质母细胞瘤患者的现成治疗。

研究设计与样本

  • 对疫苗接种后NLGN4X四聚体分选T细胞进行液滴单细胞TCR测序以发现TCR。
  • 将鉴定的TCR导入Jurkat T细胞和原代人T细胞(NLGN4X-TCR-T)。
  • 通过流式细胞术和细胞毒性实验对NLGN4X-TCR-T进行功能分析。
  • 在荷NLGN4X表达实验性胶质瘤的NOD scid gamma(NSG)主要组织相容性复合体(MHC)I/II敲除(KO)小鼠中评估脑室内NLGN4X-TCR-T的治疗疗效。

主要发现

  • 鉴定的HLA-A*02限制性疫苗诱导TCR特异性结合NLGN4X131-139,用于临床前治疗。
  • NLGN4X特异性TCR在多种细胞模型中显示反应性、细胞毒性和多功能性。
  • 脑室内给予NLGN4X-TCR-T延长实验性胶质瘤NSG MHC I/II KO小鼠生存,客观缓解率为44.4%,对照组为0.0%。

局限性

  • 结论基于临床前胶质母细胞瘤模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuroligin 4 X-linked (NLGN4X) harbors a human leukocyte antigen (HLA)-A*02-restricted tumor-associated antigen, overexpressed in human gliomas, that was found to induce specific cytotoxic T cell responses following multi-peptide vaccination in patients with newly diagnosed glioblastoma. METHODS: T cell receptor (TCR) discovery was performed using droplet-based single-cell TCR sequencing of NLGN4X-tetramer-sorted T cells postvaccination. The identified TCR was delivered to Jurkat T cells and primary human T cells (NLGN4X-TCR-T). Functional profiling of NLGN4X-TCR-T was performed by flow cytometry and cytotoxicity assays. Therapeutic efficacy of intracerebroventricular NLGN4X-TCR-T was assessed in NOD scid gamma (NSG) major histocompatibility complex (MHC) I/II knockout (KO) (NSG MHC I/II KO) mice bearing NLGN4X-expressing experimental gliomas. RESULTS: An HLA-A*02-restricted vaccine-induced T cell receptor specifically binding NLGN4X131-139 was applied for preclinical therapeutic use. Reactivity, cytotoxicity, and polyfunctionality of this NLGN4X-specific TCR are demonstrated in various cellular models. Intracerebroventricular administration of NLGN4X-TCR-T prolongs survival and leads to an objective response rate of 44.4% in experimental glioma-bearing NSG MHC I/II KO mice compared to 0.0% in control groups. CONCLUSION: NLGN4X-TCR-T demonstrate efficacy in a preclinical glioblastoma model. On a global scale, we provide the first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.Keywords cell therapy | glioblastoma | T cell receptor | tumor antigen.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Krämer C, Kilian M, Chih YC, et al. NLGN4X TCR transgenic T cells to treat gliomas. Neuro Oncol. 2024. PMID: 37715782. doi:10.1093/neuonc/noad172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。